Durant F - Search Results

1

Secondary structure of monoamine oxidase by FTIR spectroscopy.

Wouters J, Ramsay R, Goormaghtigh E, Ruysschaert JM, Brasseur R, Durant F. Wouters J, et al. Among authors: durant f. Biochem Biophys Res Commun. 1995 Mar 17;208(2):773-8. doi: 10.1006/bbrc.1995.1404. Biochem Biophys Res Commun. 1995. PMID: 7695635

2

Rational approaches towards reversible inhibition of type B monoamine oxidase. Design and evaluation of a novel 5H-Indeno[1,2-c]pyridazin-5-one derivative.

Ooms F, Frédérick R, Durant F, Petzer JP, Castagnoli N, Van der Schyf CJ, Wouters J. Ooms F, et al. Among authors: durant f. Bioorg Med Chem Lett. 2003 Jan 6;13(1):69-73. doi: 10.1016/s0960-894x(02)00838-7. Bioorg Med Chem Lett. 2003. PMID: 12467619

3

Experimental and theoretical study of reversible monoamine oxidase inhibitors: structural approach of the active site of the enzyme.

Wouters J, Moureau F, Vercauteren DP, Evrard G, Durant F, Koenig JJ, Ducrey F, Jarreau FX. Wouters J, et al. Among authors: durant f. J Neural Transm Suppl. 1994;41:313-9. doi: 10.1007/978-3-7091-9324-2_41. J Neural Transm Suppl. 1994. PMID: 7931244

4

A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action.

Wouters J, Moureau F, Evrard G, Koenig JJ, Jegham S, George P, Durant F. Wouters J, et al. Among authors: durant f. Bioorg Med Chem. 1999 Aug;7(8):1683-93. doi: 10.1016/s0968-0896(99)00102-9. Bioorg Med Chem. 1999. PMID: 10482460

5

Molecular interaction between reversible MAO-A inhibitors and the enzyme. Application to aryloxazolidinone, a prototype series.

Ooms F, Jegham S, George P, Durant F, Wouters J. Ooms F, et al. Among authors: durant f. Neurobiology (Bp). 2000;8(1):81-98. Neurobiology (Bp). 2000. PMID: 11008880 Review.

6

Structural approach of human MAO-A using fold recognition (threading) techniques.

Wouters J, Depiereux E, Durant F. Wouters J, et al. Among authors: durant f. Neurobiology (Bp). 2000;8(1):119-28. Neurobiology (Bp). 2000. PMID: 11008883

7

Three 5H-indeno[1,2-c]pyridazin-5-one derivatives, potent type-B monoamine oxidase inhibitors.

Frédérick R, Norberg B, Durant F, Ooms F, Wouters J. Frédérick R, et al. Among authors: durant f. Acta Crystallogr C. 2004 Sep;60(Pt 9):o623-6. doi: 10.1107/S0108270104014660. Epub 2004 Aug 11. Acta Crystallogr C. 2004. PMID: 15345837

8

Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach.

Charlier C, Hénichart JP, Durant F, Wouters J. Charlier C, et al. Among authors: durant f. J Med Chem. 2006 Jan 12;49(1):186-95. doi: 10.1021/jm050870x. J Med Chem. 2006. PMID: 16392803

9

Kinetic characterization of tyramine oxidase of Arthrobacter species.

Wouters J, Perpète P, Hayen P, Anceau N, Durant F. Wouters J, et al. Among authors: durant f. Biochem Mol Biol Int. 1994 Mar;32(4):737-43. Biochem Mol Biol Int. 1994. PMID: 8038724

10

Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors.

Ooms F, Wouters J, Collin S, Durant F, Jegham S, George P. Ooms F, et al. Among authors: durant f. Bioorg Med Chem Lett. 1998 Jun 2;8(11):1425-30. doi: 10.1016/s0960-894x(98)00230-3. Bioorg Med Chem Lett. 1998. PMID: 9871778

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters